Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

To date, loop diuretics are the mainstay treatment for decongestion in patients with acute decompensated heart failure (HF). In clinical practice, loop diuretics have also been utilized for patients with chronic HF with reduced and preserved ejection fractions. There is a paucity of quality evidence of the effect of loop diuretics use and dosing on clinical outcomes in HF patients beyond symptomatic relief. In this review, we aimed to summarize recently published data on the use of loop diuretics in patients with HF, focusing on efficacy and safety outcomes in patients with HF with reduced and preserved ejection fraction. We searched EMBASE, PubMed, CINAHL, and the "Web of Science" databases. Cohort studies and randomized controlled trials published after 2018 and written in English were included in this review. Case reports, case series, cross-sectional studies, review articles, commentaries, articles published more than five years ago, and studies involving children were excluded. Results were divided into the efficacy and safety of loop diuretics in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). A registry-based study included in our review observed a reduced 30-day all-cause mortality in patients with HFrEF receiving loop diuretics compared to those not receiving loop diuretics (HR=0.73; 95% CI=0.57-0.94; p=0.016), but there was no statistically significant association at the 60-day follow-up of the same group of patients. Most studies reviewed showed that the choice of loop diuretics did not influence clinical outcomes such as mortality and HF rehospitalization in patients with HF with reduced and preserved ejection fraction despite differences in oral bioavailability and half-life. Studies have consistently shown that patients with HF who receive a higher dose of loop diuretics are likely to experience a decline in renal function and hypotension, regardless of their type of HF. Discontinuation or reduction of the dose of loop diuretics should be considered in patients with HF after decongestion.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590658PMC
http://dx.doi.org/10.7759/cureus.45794DOI Listing

Publication Analysis

Top Keywords

loop diuretics
44
ejection fraction
24
preserved ejection
20
efficacy safety
12
reduced preserved
12
loop
11
diuretics
11
patients
11
safety loop
8
diuretics patients
8

Similar Publications

This systematic review explores the impact of diuretic timing and strategy on outcomes in patients with acute decompensated heart failure (ADHF). A total of seven studies were included, comprising randomized controlled trials (RCTs), pre-specified sub-analyses, and observational data. Early administration of intravenous loop diuretics, particularly within the first 60 to 90 minutes of hospital arrival, was generally associated with improved short-term outcomes, including reduced in-hospital and 30-day mortality.

View Article and Find Full Text PDF

IV loop diuretics remain the cornerstone of treatment for acute decompensated heart failure (ADHF). Although previous meta-analyses have compared continuous infusion and intermittent bolus dosing of IV loop diuretics, their respective renal effects remain unclear. Given the prognostic significance of worsening renal function (WRF) or acute kidney injury in ADHF, evaluating the renal safety of different diuretic regimens is essential.

View Article and Find Full Text PDF

Introduction: Drug-drug interactions (DDIs) have been associated with adverse drug reactions (ADRs) which can cause hospitalization. The aim of this study was to associate potential DDIs (pDDIs) with potential ADRs upon admission to hospital among patients on five internal medicine wards.

Materials And Methods: A cross-sectional study was performed on the cardiology, nephrology, endocrinology, gastroenterology, and geriatrics ward.

View Article and Find Full Text PDF

Application of health data analytics in pharmacy - An innovative approach to developing a heart failure dashboard.

J Am Pharm Assoc (2003)

August 2025

Monash Healthxe , 361 Blackburn Rd , Clayton Melbourne, Australia; Monash University Wellington Rd, Clayton . Melbourne Australia; Victorian Heart Hospital, Monash Health, Clayton, VIC, Australia.

Background: There has been increasing interest in the utilisation of health data analytics for decision support systems and prioritising pharmacy clinical work. Despite this potential, there remains limited evidence in the Australian context regarding the design and implementation of data-driven dashboards tailored specifically for pharmacists.

Objectives: We aimed to develop a disease state dashboard in an Australian hospital to assist clinicians identifying and prioritising the review of heart failure (HF) patients when admitted for other reasons, enabling timely optimisation of their care.

View Article and Find Full Text PDF

Background: Patients with atrial fibrillation (AF) and chronic obstructive pulmonary disease (COPD) are at increased risk of cardiovascular mortality compared to patients with AF alone. Consequently, employing rhythm control strategies such as AF catheter ablation could offer substantial benefits to patients with COPD. However, the impact of COPD on AF ablation outcomes is not well established.

View Article and Find Full Text PDF